       Document 0425
 DOCN  M9630425
 TI    Use of zidovudine in human immunodeficiency virus-induced hepatitis.
 DT    9603
 AU    Wertheim DL; Valderamma E; Bonagura VR; Division of Allergy and
       Immunology, Schneider Children's; Hospital, New Hyde Park, New York
       11042, USA.
 SO    Clin Diagn Lab Immunol. 1994 May;1(3):361-3. Unique Identifier :
       AIDSLINE MED/96050839
 AB    Hepatitis is a common complication of human immunodeficiency virus (HIV)
       disease in children. Often a distinct pathogen cannot be identified.
       Therefore, by exclusion, one must consider HIV the direct pathogen.
       Zidovudine (AZT) has not been used as a treatment for HIV-positive
       children with presumed HIV-induced hepatitis because of the potential of
       this medication to exacerbate preexisting hepatitis. We have used AZT to
       treat an 8-month-old female with severe HIV-induced hepatitis and have
       achieved complete remission with this regimen. For some HIV-positive
       children with HIV-induced hepatitis, AZT may be the drug of choice to
       resolve hepatic inflammation caused by this virus.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS  Case Report  Female
       Hepatitis, Chronic Active/*DRUG THERAPY/*ETIOLOGY/PATHOLOGY  Human
       Infant  Zidovudine/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

